Success Metrics

Clinical Success Rate
80.0%

Based on 4 completed trials

Completion Rate
80%(4/5)
Active Trials
1(14%)
Results Posted
100%(4 trials)
Terminated
1(14%)

Phase Distribution

Ph phase_1
3
43%
Ph phase_2
4
57%

Phase Distribution

3

Early Stage

4

Mid Stage

0

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
3(42.9%)
Phase 2Efficacy & side effects
4(57.1%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

66.7%

4 of 6 finished

Non-Completion Rate

33.3%

2 ended early

Currently Active

1

trials recruiting

Total Trials

7

all time

Status Distribution
Active(1)
Completed(4)
Terminated(2)

Detailed Status

Completed4
Recruiting1
Terminated1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
1
Success Rate
80.0%
Most Advanced
Phase 2

Trials by Phase

Phase 13 (42.9%)
Phase 24 (57.1%)

Trials by Status

recruiting114%
terminated114%
completed457%
withdrawn114%

Recent Activity

1 active trials
Showing 5 of 7
recruitingphase_2

Efficacy and Safety of Tenalisib in Patients With Metastatic Triple Negative Breast Cancer (TNBC)

NCT06189209
completedphase_2

Efficacy and Safety of Tenalisib (RP6530) in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

NCT04204057
completedphase_1

Compassionate Use Study of Tenalisib (RP6530)

NCT03711604
completedphase_1

Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed/Refractory T-cell Lymphoma

NCT03770000
withdrawnphase_2

Study to Evaluate the Efficacy and Safety of Tenalisib, Given With CHOP Therapy for Front Line Treatment in Patients With PTCL

NCT05239910
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT06189209Phase 2

Efficacy and Safety of Tenalisib in Patients With Metastatic Triple Negative Breast Cancer (TNBC)

Recruiting
NCT04204057Phase 2

Efficacy and Safety of Tenalisib (RP6530) in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Completed
NCT03711604Phase 1

Compassionate Use Study of Tenalisib (RP6530)

Completed
NCT03770000Phase 1

Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed/Refractory T-cell Lymphoma

Completed
NCT05239910Phase 2

Study to Evaluate the Efficacy and Safety of Tenalisib, Given With CHOP Therapy for Front Line Treatment in Patients With PTCL

Withdrawn
NCT03711578Phase 2

Efficacy and Safety Study of Tenalisib (RP6530), a Novel PI3K δ/γ Dual Inhibitor in Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (iNHL)

Completed
NCT03471351Phase 1

Safety and Efficacy Study of Tenalisib (RP6530) in Combination With Pembrolizumab in Relapsed or Refractory cHL

Terminated

All 7 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
7